Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Alvarion, Perrigo, Ratio Oil, Teva: Israeli Equity Preview

May 3 (Bloomberg) -- The following stocks may rise or fall in Israeli markets. Stock symbols are in parentheses after the company names and prices are from the last close unless otherwise stated.

The TA-25 Index lost 0.3 percent to 1,291.89 in Tel Aviv.

Alvarion Ltd. (ALVR IT): The maker of wireless telecommunications equipment said its first-quarter loss widened to $14.5 million from $4.9 million a year earlier. Alvarion climbed 1 percent to 5.765 shekels.

Perrigo Co. (PRGO IT): The maker of over-the-counter drugs received a final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for over-the-counter Minoxidil foam, a generic version of Men’s Rogaine Foam, a hair-growth treatment. Perrigo, which is scheduled to report fiscal third-quarter results today, declined 0.6 percent to 299.50 shekels.

Ratio Oil Exploration 1992 LP (RATIL IT): The oil and gas explorer is offering up to 500 million partnership units at 0.44 shekel each. Ratio was unchanged at 0.452 shekel.

Teva Pharmaceutical Industries Ltd. (TEVA IT): The world’s largest maker of generic drugs plans to acquire Taiyo Pharmaceutical Industry Co. for about 40 billion yen ($490 million), the Nikkei newspaper reported yesterday. Teva rose 3.5 percent to 161.20 shekels.

To contact the reporter on this story: Sharon Wrobel in Tel Aviv at swrobel4@bloomberg.net

To contact the editor responsible for this story: Claudia Maedler at cmaedler@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.